MetaCap

Neuropace Inc. (NPCE)

NASDAQ: NPCEHealth CareMedical/Dental InstrumentsUSD

7.95-0.19 (-2.33%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NPCE stock chart

Technical analysis

Key statistics

All statistics
Market cap
$273.89M
EPS (TTM)
-$0.56
52-week range
5.46 – 19.60
Day range
7.85 – 8.29
Volume / Avg
749.38K / 270.76K
Beta
—

52-week range

$5.46$19.60

NPCE stock today

Neuropace (NPCE) closed at $7.95 on Nov 20, down 2.33% (-$0.19), versus the S&P 500's 3.70% decline. Volume was 2.8x the average at 749.38K shares, a sign of unusually heavy trading. At this level, NPCE sits near the bottom of its 52-week range of $5.46 to $19.60: 59.4% below the high, set on May 8, 2026 and 45.6% above the low.

NPCE is down 48.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 44.6%. Neuropace has posted a net loss over the last twelve months (EPS of -$0.56), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Neuropace

Company profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.

Industry
Medical/Dental Instruments
CEO
Mr. Joel D. Becker
Headquarters
Mountain View, CA
Employees
216
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Neuropace generated $100.0 million in revenue, up 25.1% from fiscal 2024, its 5th consecutive year of revenue growth. Neuropace reported a net loss of $21.5 million, compared with a loss of $27.1 million a year earlier. Gross margin was 77.2% (up from 73.9%) and operating margin -16.3%.

Neuropace annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$99.99M$79.91M$65.42M$45.52M$45.18M
Growth+25.13%+22.14%+43.72%+0.75%+9.83%
Net income$-21.46M$-27.14M$-32.96M$-47.08M$-36.08M
EPS (diluted)$-0.66$-0.93$-1.27$-1.91$-2.17

Analyst forecast

Forecast

Consensus (10 analysts)

buy

Avg. price target

$12.22+53.71%

  • Strong buy 0
  • Buy 6
  • Hold 4
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $22.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.11 vs $-0.14
Surprise
+21.43%

NPCE news

All NPCE news

Neuropace peers

Health Care sector
NPCE peer companies
CompanyPrice% ChgMarket capCompare
TMCITreace Medical Concepts Inc.4.31-0.92%$282.56Mvs NPCE
INFUInfuSystems Holdings Inc.14.35+2.06%$287.48Mvs NPCE
SSIISS Innovations International Inc.1.27-0.78%$254.86Mvs NPCE
OFIXOrthofix Medical Inc.6.07-4.26%$247.41Mvs NPCE
OSUROraSure Technologies Inc.3.46-4.16%$238.90Mvs NPCE
PROFProfound Medical Corp.6.38-3.19%$233.68Mvs NPCE
CLPTClearPoint Neuro Inc.6.91-5.47%$221.49Mvs NPCE
EMBCEmbecta Corp.6.02-2.75%$341.09Mvs NPCE

Indexes, lists and sector

Neuropace stock FAQ

What is Neuropace's stock price today?

NPCE last traded at $7.95 as of Nov 20, 4:00 PM EST, down 2.33% on the day. Prices are delayed at least 15 minutes.

Who is Neuropace's CEO?

Mr. Joel D. Becker is the chief executive officer of Neuropace Inc., which has about 216 employees.

What is the NPCE 52-week high?

The 52-week high for NPCE is $19.60 and the 52-week low is $5.46. The stock is currently 59.4% below its high.

Compare NPCE